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Abstract
Background: The feasibility of significant weight reduction in a specialist arrhythmia 
service, and its impact on atrial fibrillation (AF) ablation outcomes are unclear. We 
aimed to assess these factors in a real-world cohort in the United Kingdom.
Methods: Patients from one specialized arrhythmia clinic were instructed to follow 
the “Intermittent Fasting 5:2 diet” (“diet group”, n = 50), and their outcomes were 
compared to a propensity matched cohort who received no specific dietary advice 
(“control group”, n = 42). The primary outcome was recurrence of AF or atrial tachy-
cardia (AT) at 12 months postablation, with or without drugs.
Results: Body weight and body mass index (BMI) at baseline were 105.0 (±15.3) kgs 
and 36.0 (±4.0), respectively. Baseline characteristics between the two groups were 
comparable. Patients in diet group experienced a mean weight loss of 8.2 (±7.1) kgs 
prior to AF ablation (P < .01 for comparison to baseline and control group). About 14 
(28%) patients in the diet group lost >10% of their body weight. Overall, 11 (22%) 
patients in the diet group and five (12%) in the control group had AF recurrence at 
1 year, P = .21. AF recurrence was similar in patients with BMI ≥ 35 (15%) as com-
pared to BMI < 35 (19%), P = .60. There was one procedural complication (pulmonary 
edema) in the diet group.
Conclusion: It is feasible to achieve significant weight reduction in obese AF patients 
in a specialist arrhythmia clinic setting with unsupervised dietary advice. Low rates of 
procedural complications and excellent medium-term success rates were observed in 
this traditionally challenging population. Additional improvements in outcomes were 
not demonstrable in patients who exhibited significant weight loss.
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1  | INTRODUC TION
Atrial fibrillation (AF) is a significant health condition that is associated 
with increased morbidity and mortality.1-4 Obesity is recognized as an 
important risk factor for AF.5,6 Obesity is associated with an increased 
left atrial size and decreased left ventricular diastolic function,7 which 
contribute to higher left atrial pressure.8,9 These changes promote the 
initiation and maintenance of AF. Overall, obesity is related to worse 
outcomes in terms of AF symptom severity, frequency of AF-related 
hospitalization, burden, and quality of life.10 Furthermore, obesity has 
adverse implications on the efficacy and safety of catheter AF ablation. 
Two independent meta-analyses demonstrated that higher preablation 
body mass index (BMI) was linked to increased AF recurrence postab-
lation.11,12 Obese patients are also exposed to higher adverse events 
from AF ablation compared to nonobese patients.13,14
Pathak and colleagues showed that targeted weight management 
in obese patients improved outcomes of AF ablation.15 On the other 
hand, Mohanty et al failed to demonstrate any benefits on ablation 
outcomes with weight reduction in patients with long-standing per-
sistent AF.16 As such, the data evaluating the role of weight reduction 
alone for improving the outcomes of catheter AF ablation are scarce 
and conflicting. Recently, the National Health Service (NHS) in the 
United Kingdom has proposed imposing severe restrictions to catheter 
ablation to obese AF patients, including the requirement to lose at least 
10% body weight for them to be eligible (circular 7th January 2020). In 
the present study, we aimed to evaluate the feasibility of weight reduc-
tion in a real-life specialist arrhythmia clinic in the United Kingdom, and 
its effects on results of catheter AF ablation.
2  | METHODS
Consecutive obese patients with symptomatic AF, with a BMI of 
greater than 30, referred to specialist arrhythmia clinics at Liverpool 
Heart and Chest Hospital for consideration of AF ablation were en-
rolled. All patients gave written informed consent for their proce-
dures, and outcome data were extracted from an institutional review 
board-approved registry. Obese patients attending one arrhythmia 
clinic were provided with the 5:2 dietary advice (diet group), and out-
comes in these were compared to a propensity score matched (PSM) 
group of obese patients who received standard medical care with 
no specific dietary advice (control group). All other aspects of the 
management were identical between the two groups. The primary 
outcome was AF or atrial tachycardia (AT) recurrence on electro-
cardiographic monitoring within 12 months postablation. Secondary 
outcomes were periprocedural complications and change in body 
weight between clinic and ablation procedure.
2.1 | Education and dietary advice
All patients in the diet group, along with their partners if available, 
were reviewed by an experienced consultant cardiologist (DG). 
Education was provided about the association between obesity and 
AF. They were counseled about the possibility that weight reduction 
could improve safety and efficacy of AF ablation, and were advised 
to follow the “Intermittent Fasting 5:2 diet”.17 This diet involves calo-
rie restriction for 2 nonconsecutive days a week (less than 600 kcal/d 
for males, less than 500 kcal/d for females) with no restrictions on 
the remaining 5 days. Patients were requested to maintain a daily 
weight diary and to contact the hospital with their weight via tel-
ephone or email on a monthly basis. They were offered catheter ab-
lation once they managed to lose at least 5 kg, or at 6 months even 
if not. This period was extended for patients who expressed a desire 
to lose more weight before coming in for their ablation.
Patients in the control group were assessed in two specialist ar-
rhythmia clinics (RS and DG) where the management strategy was 
identical to those in the diet group, except that specialist dietary ad-
vice was not offered and weight loss was not specifically targeted.
2.2 | Ablation procedure in both groups
Catheter ablation was performed either using point-by-point radi-
ofrequency (RF) using CARTO or with a cryoballoon catheter. All RF 
pulmonary vein isolation (PVI) procedures were performed with wide-
area circumferential ablation using a Thermocool SmartTouch irri-
gated tip contact force-sensing ablation catheter (Biosense Webster, 
Inc, California) through a deflectable sheath (Agilis NxT steerable in-
troducer, Abbott, Inc, Minnesota). Ablations were delivered at least 
10 mm outside the pulmonary vein (PV) ostia, in a power-control 
mode with temperature limited to 48°C, maximal power output of 
35-40 W, and saline irrigation rate of 17 mL/min. Automated lesion 
tagging (VisiTagTM, Biosense Webster, Inc, California) was used for RF 
lesion marking, with a lesion display size of 3 mm. An intertag distance 
of ≤6 mm was aimed for, with target ablation index of >400 and ≥550 
at the posterior and anterior walls, respectively. In cases performed 
under general anesthesia, esophageal temperature was monitored 
continuously, and RF delivery terminated if the esophageal tempera-
ture reached 38.5°C, or earlier at the operator's discretion. All patients 
were set out to have PVI-only unless they had documented cavo-tri-
cuspid isthmus (CTI)-dependent atrial flutter, in which case they also 
received CTI ablation. Patients with long-standing persistent AF and 
dilated atria also underwent posterior wall isolation with creation of 
left atrial roof and floor lines at the operator's discretion. Prior to re-
moval of the left atrial catheters, an assessment of each PV was under-
taken. Any spontaneous PV reconnection was re-isolated.
Cryoballoon ablation was performed using the 28 mm Arctic 
Front Advance cryoballoon (Medtronic Inc, Minneapolis, USA) and 
Achieve Advance Mapping catheter (Medtronic Inc, Minneapolis, 
USA). The aim was to attain a single 180 second “effective” freeze 
for each PV. A freeze is considered “effective” if either the time to 
PVI was less than 60s (if PV signals are discernible on any pole of 
the mapping catheter), or lowering of balloon temperature below 
−40°C at 60s (if PV signals not discernible on any pole of the map-
ping catheter).
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Intravenous sheaths were removed following administration of 
intravenous protamine. Patients were mobilized after 4 hours bed 
rest, and discharged home the next day.
2.3 | Follow-up
Routine follow-up visits were arranged at 3, 6, and 12 months. A 12-
lead electrocardiogram was recorded at each visit. Holter and other 
forms of ambulatory monitoring were performed for patients who 
had paroxysmal symptoms.
2.4 | Statistical analyses
Continuous data were described with mean ± standard devia-
tion (SD), and tested for differences using t-test. Categorical data 
were described with counts and/or percentages, and tested for dif-
ferences using Chi-squared or Fisher's exact tests. Patients were 
matched based on propensity score generated by logistic regres-
sions for age, sex, and AF type (paroxysmal/ nonparoxysmal) and 
preprocedural clinic BMI with a match tolerance of 0.1 and using the 
nearest-neighbor technique without replacement. Incidence of AF/
AT recurrence at 1 year was compared using logistic regression. The 
timing of AF/AT recurrence was contrasted using log-rank test, and 
Kaplan-Meier curves were generated. Subgroup analysis was per-
formed within the diet group according to the amount of weight loss 
achieved prior to ablation: loss ≤10% of body weight (Group A) and 
loss >10% body weight (Group B). All tests were two-sided, and a P 
value of <.05 was considered statistically significant. Analyses were 
performed using SPSS software version 24 (IBM Corp, Armonk, NY).
2.5 | Patient and public involvement
Our patients were not involved in designing of, recruitment to, or 
conduct of the present study.
3  | RESULTS
Fifty patients were provided with the 5:2 dietary advice while 92 
received standard medical care. Following PSM, 92 patients (50 diet; 
42 control) were included in the final analysis. Mean age was 64.6 
(±9.1) years and 40 (44%) were females. Body weight and BMI at 
baseline were 105.0 (±15.3) kgs and 36.0 (±4.0), respectively. Fifty-
two (57%) patients had nonparoxysmal AF including 34 (37%) with 
long-standing persistent AF. Baseline clinical characteristics were 
comparable between the two groups (Table 1).
Patients in the diet group achieved significantly more weight 
loss before their catheter ablation procedure compared to those in 
the control group (P < .01). Following a median of 5.3 (IQR 1.4-15.6) 
months, the former group achieved a mean weight loss of 8.2 (±7.1) 
kgs, P < .01 compared to baseline, and their BMI at the time of the 
ablation procedure was 33.7 (±4.2), P < .01 compared to baseline. 
However, this was variable between patients; 36 (72%) patients 
achieved weight loss of less than 10% body weight (Group A) and 
14 (28%) achieved weight loss greater than 10% body weight (Group 
B). About 37 (74%) patients achieved weight loss of greater than 5% 
body weight.
The ablation procedures were performed successfully in all 92 
patients. The mean procedure duration was 152 (±94) minutes, and 
the mean ablation time was 31 (±15) minutes. Seventy (76%) patients 
underwent RF ablation while 22 (24%) underwent cryoballoon PVI. 
More patients underwent posterior wall isolation in the diet group 
(44%) compared to controls (19%), P = .011. One procedural com-
plication (1.1%) occurred in the entire cohort. This patient from the 
diet group developed postablation pulmonary edema that required 
management on intensive care overnight, and delayed hospital dis-
charge by 2 days.
Overall, 16 (17%) patients had AF/AT recurrence at 1 year. The 
rate of AF/AT recurrence in this period was not significantly differ-
ent between the groups, 22% diet vs 12% control, P = .21 (Table 2). 
The mean follow-up duration for the diet group was 23.3 (±11.4) 
months and for the control group was 24.3 (±13.5) months, P = .69. 
Using Kaplan-Meier analysis, the freedom from AF/AT was similar in 
both groups, log-rank P = .13 (Figure 1).
3.1 | Outcomes according to extent of weight loss
Body weight at the time of ablation was 100.9 (±16.8) kgs and 96.3 
(±14.8) kgs, and BMI was 34.3 (±4.2) and 32.4 (±3.9) for Groups A and 
B, respectively. Only four (8%) patients had World Health Organization 
Class III obesity (BMI ≥ 40) at the time of ablation as compared to 11 
TA B L E  1   Baseline characteristics
Diet
(n = 50)
Control
(n = 42)
P 
value
Age (y), mean ± SD 64.9 ± 9.5 64.1 ± 8.7 .66
Female sex 25 (50%) 15 (36%) .17
BMI, mean ± SD 36.5 ± 4.0 35.3 ± 3.9 .16
Ischemic heart disease 5 (10%) 1 (2%) .21
LA size (mm), 
mean ± SD
41.9 ± 5.2 41.7 ± 5.1 .88
Paroxysmal AF 19 (38%) 21 (50%) .25
Medications
Beta-blockers 43 (86%) 35 (83%) .72
Non-dihydropyridine 
CCB
5 (10%) 2 (5%) .45
AAD class I 11 (22%) 3 (7%) .08
AAD class III 10 (20%) 7 (17%) .68
Abbreviations: AAD, anti-arrhythmic drug; AF, atrial fibrillation; BMI, 
body mass index; CCB, calcium-channel blocker; LA, left atrial; SD, 
standard deviation.
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(22%) patients at time of initial assessment, P = .03. The recurrence 
of AF/AT at 12 months was significantly higher in Group B (42.9% vs 
13.9%), P = .04. However, Kaplan-Meier analysis demonstrated no 
statistical difference in AF/AT recurrence between the groups over a 
30 month follow-up period, log-rank P = .13 (Figure 2).
3.2 | Outcomes according to BMI at procedure
We performed further analyses according to patients’ BMI at the 
time of procedure. Fifty-eight (63%) patients had a BMI < 35 and 
34 (37%) patients had a BMI ≥ 35. There was no difference in out-
comes of AF/AT recurrence at 1 year between these groups, 15% 
(BMI ≥ 35) vs 19% (BMI < 35), P = .60 (Table 3). Kaplan-Meier analy-
sis demonstrated similar results over a 30-month follow-up period, 
log-rank P = .40 (Figure 3).
4  | DISCUSSION
This “real-world” study demonstrates that (a) it is possible to achieve 
significant weight reduction in obese AF patients in a nonbariatric ar-
rhythmia clinic with simple education and dietary advice, (b) modern 
AF ablation has excellent procedural safety as well as medium-term 
arrhythmia-free survival rates in this traditionally difficult population 
of obese patients with a high proportion of nonparoxysmal AF, and 
(c) significant weight reduction, even beyond the proposed thresh-
old of over 10% body weight, is achievable but in isolation does not 
appear to translate to better arrhythmia outcomes.
Physicians are sometimes reluctant to consider AF ablation in 
obese patients because of the perceived higher complication risks 
and poor success rates.11-14 As such, health systems are reviewing 
the cost efficacy of AF ablation in this cohort. In fact, NHS England 
has recently released a draft of their proposed commissioning guide-
lines according to which AF ablation will not be offered to patients 
with BMI greater than 40, and patients with BMI between 35 and 40 
will need to demonstrate weight reduction of at least 10% of their 
body weight before being eligible for AF ablation. The feasibility 
of this degree of weight reduction in patients referred to a stand-
alone specialist arrhythmia clinic with no support from bariatric or 
dietetic services has never been studied. Furthermore, with the re-
cent advances in AF ablation techniques and protocols, its efficacy 
and safety in this cohort of patients need to be re-evaluated in a 
contemporary series. We have seen in our study that the major com-
plication rates were low. This is almost certainly because the most 
common complications of AF ablation have historically been related 
to vascular access, and these are particularly more likely in obese 
patients.18,19 Since the introduction of ultrasound to obtain vascu-
lar access, these complications have been all but eradicated.20 The 
TA B L E  2   Efficacy of AF ablation at 1 year in control vs diet 
group
Diet 
(n = 50)
Control 
(n = 42)
P 
value
AF recurrence 11 (22%) 5 (12%) .21
Symptom frequency
Improved 7 (64%) 4 (80%)
Unchanged 4 (36%) 1 (20%)
Symptom duration
Improved 6 (55%) 4 (80%)
Unchanged 5 (46%) 1 (20%)
Further cardioversion 7 (64%) 2 (40%)
Abbreviation: AF, atrial fibrillation.
F I G U R E  1   Kaplan-Meier analysis 
of freedom from AF recurrence in diet 
vs control group
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risk of cardiac tamponade has been mitigated in recent years by the 
use of transesophageal echocardiography to guide transseptal punc-
tures, and the introduction of contact force-sensing and cryoballoon 
ablation catheters, both of which were used in this study.
Recently, several studies from a single center have been pub-
lished demonstrating the benefits of weight loss in patients with 
AF.15,21-23 Of these, the ARREST-AF trial was designed to evaluate 
outcomes specifically in patients undergoing AF ablation. It is im-
portant to note that these studies employed a multifactorial risk 
factor modification approach that included blood pressure control, 
lipid management, glycemic control, sleep-disordered breathing 
management, and smoking cessation and alcohol reduction sup-
port.15 On the other hand, in a study focused on weight reduction 
alone, Mohanty et al showed no correlation between weight loss and 
success of ablation in patients with long-standing persistent AF.16 As 
such, the role of weight loss on the success of catheter AF ablation 
remains poorly established.
Our findings are consistent with those by Mohanty 
et al Furthermore, BMI at the time of procedure was not associated 
with outcomes of AF ablation in our obese cohort. This may indicate 
that certain features of cardiac remodeling secondary to obesity24 
may be irreversible. Indeed, some studies have shown that despite 
improvement in left ventricular parameters with weight loss in obese 
patients, the left atrial size remained fixed.25-27 Consequently, sim-
ilar to structural and electrical remodeling due to AF, irreversible 
changes may occur once a certain obesity threshold is exceeded. In 
addition, any possible benefits of weight loss need to be balanced 
against the significant time taken for weight loss measures to take 
effect. It is well described that increasing duration of AF has nega-
tive effects on ablation success rates. In our study, the median time 
from clinic to ablation procedure among patients who achieved more 
than 10% weight loss in the diet group was 10 months, and this delay 
may have contributed to the observation of higher AF recurrence. 
Nonetheless, it is important to recognize that though weight loss in 
obese patients may not reduce AF recurrence postablation, it may 
have several other important health benefits and we continue to be-
lieve that it should be encouraged among these patients.
Weight loss can be challenging for obese patients who are 
symptomatic from AF. In the ARREST-AF trial, this was achieved 
through a dedicated physician-directed weight management clinic.15 
Participants were provided with motivational and goal-directed 
counseling, a meal plan, behavior modification, a diet and physical 
activity diary, and a meal replacement as required. Despite evidence 
to support the cost-effectiveness of this strategy in one specialized 
medical center in Australia,28 it may not be applicable globally to the 
F I G U R E  2   Kaplan-Meier analysis of 
freedom from AF recurrence based on 
weight reduction in the diet group
TA B L E  3   Efficacy of AF ablation at 1 year according to BMI at 
the time of ablation
BMI < 35 
(n = 58)
BMI ≥ 35 
(n = 34)
P 
value
BMI, mean ± SD 31.9 ± 1.8 38.8 ± 3.1 <.01
AF recurrence 11 (19%) 5 (15%) .60
Symptom frequency
Improved 7 (64%) 4 (80%)
Unchanged 4 (36%) 1 (20%)
Symptom duration
Improved 6 (55%) 4 (80%)
Unchanged 5 (46%) 1 (20%)
Further cardioversion 6 (55%) 3 (60%)
Abbreviations: AF, atrial fibrillation; BMI, body mass index; SD, standard 
deviation.
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general medical and cardiology clinics, where the majority of pa-
tients with AF are managed. Indeed, to the best of our knowledge, 
those impressive results have not yet been replicated by any other 
center. Therefore, it is important to identify simple and practical 
tools that may be used to encourage weight loss in these situations. 
To this end, we have shown that simple dietary advice of intermit-
tent fasting 5:2 diet may be effective in promoting weight loss in 
obese patients with AF, whereby three-quarters of patients were 
able to lose at least 5% of their baseline body weight prior to AF 
ablation. Furthermore, it may be incorporated into their usual clinic 
review without the need to commit additional resources.
4.1 | Limitations
The main limitation of this study is its retrospective observational 
study design and small sample size which may lead to variability in the 
results obtained. These factors together with a greater proportion 
(though not statistically significant) of patients with nonparoxysmal 
AF in those who had >10% weight loss in the diet group may have 
contributed to the counter-intuitive results of higher AF recurrence 
in this group of patients. However, some of the weaknesses typically 
associated with an observational study design were addressed using 
PSM. A second limitation is that we were unable to confirm whether 
the weight loss was sustained in a significant proportion of patients. 
The importance of sustained weight loss postablation was previously 
demonstrated to be associated with a lower AF recurrence rate.29 
Among the 22 (44%) in the diet group, where these data are available, 
the weight loss achieved preablation was maintained during follow-
up in all. Thirdly, the success rates described in this study are “prag-
matic” success rates, as evaluated from a patient's clinical perspective 
with limited electrocardiographic monitoring. It is likely that some 
instances of asymptomatic paroxysmal AF would have been missed. 
The post hoc analysis of patients according to BMI subgroups in-
cludes a heterogeneous cohort of patients who received dietary ad-
vice and controls, and therefore should be interpreted with caution.
5  | CONCLUSIONS
We show that significant weight reduction in obese AF patients is 
achievable in a tertiary arrhythmia clinic with simple dietary advice. 
Excellent outcomes of catheter AF ablation are seen in this histori-
cally difficult cohort with modern ablation techniques. Significant 
weight loss alone does not translate to better outcomes; whether 
this is because of advanced arrhythmia substrate by the time pa-
tients are referred to an arrhythmia clinic, or because of the as-
sociated delay in ablation caused by the efforts at further weight 
reduction needs to be evaluated in further studies.
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